Characteristics of COVID-19 in patients with multiple sclerosis.

Autor: Ghadiri F; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Sahraian MA; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Shaygannejad V; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Ashtari F; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Ghalyanchi Langroodi H; Center for Clinical Research and development, Ghaem Int. Hospital, Rasht, Iran., Baghbanian SM; Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran., Mozhdehipanah H; Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran., Majdi-Nasab N; Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Hosseini S; Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Poursadeghfard M; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran., Beladimoghadam N; Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Razazian N; Department of Neurology, Medicine Faculty, Kermanshah University of Medical Sciences, Kermanshah, Iran., Ayoubi S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Rezaeimanesh N; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Eskandarieh S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: sh_eskandarieh@yahoo.com., Naser Moghadasi A; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: abdorrezamoghadasi@gmail.com.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Jan; Vol. 57, pp. 103437. Date of Electronic Publication: 2021 Nov 30.
DOI: 10.1016/j.msard.2021.103437
Abstrakt: Background: Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population.
Methods: Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe.
Results: A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms.
Conclusion: The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: